253 related articles for article (PubMed ID: 29346270)
1. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Charpentier C; Descamps D
Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.
Anstett K; Cutillas V; Fusco R; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2016 Aug; 71(8):2083-8. PubMed ID: 27084918
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
Charpentier C; Malet I; Andre-Garnier E; Storto A; Bocket L; Amiel C; Morand-Joubert L; Tumiotto C; Nguyen T; Maillard A; Rodallec A; Leoz M; Montes B; Schneider V; Plantier JC; Dina J; Pallier C; Mirand A; Roussel C; Signori-Schmuck A; Raymond S; Calvez V; Delaugerre C; Marcelin AG; Descamps D
J Antimicrob Chemother; 2018 Apr; 73(4):1039-1044. PubMed ID: 29342281
[TBL] [Abstract][Full Text] [Related]
5. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M; Chiarella J; Kozal MJ
Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
[TBL] [Abstract][Full Text] [Related]
6. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
7. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
8. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
9. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
10. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
11. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
12. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
Pham HT; Mesplède T; Wainberg MA
Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
[TBL] [Abstract][Full Text] [Related]
14. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
Mesplède T; Quashie PK; Hassounah S; Osman N; Han Y; Liang J; Singhroy DN; Wainberg MA
AIDS; 2015 Jul; 29(12):1459-66. PubMed ID: 26244385
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
Saladini F; Meini G; Bianco C; Monno L; Punzi G; Pecorari M; Borghi V; Di Pietro M; Filice G; Gismondo MR; Micheli V; Penco G; Carli T; De Luca A; Zazzi M;
Clin Microbiol Infect; 2012 Oct; 18(10):E428-30. PubMed ID: 22716970
[TBL] [Abstract][Full Text] [Related]
16. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
[TBL] [Abstract][Full Text] [Related]
17. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.
Mesplède T; Wainberg MA
Viruses; 2015 Jul; 7(7):3703-18. PubMed ID: 26198244
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
[TBL] [Abstract][Full Text] [Related]
19. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
[TBL] [Abstract][Full Text] [Related]
20. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
